Literature DB >> 2529097

A sensitive bioassay for teicoplanin in serum in the presence or absence of other antibiotics.

R C Erickson1, A R Hildebrand, P F Hoffman, C B Gibson.   

Abstract

A teicoplanin bioassay has been developed that is accurate, sensitive, and reliable. A linear relationship is obtained between the diameter of the zone of inhibition and log10 teicoplanin concentration in human serum over the range of 0.15 or 1.25 to 96 micrograms/ml using wells or paper filter disks, respectively. The assay medium devised consists of 50 g BBL Mueller-Hinton II Agar, 30 g NaCl, 8 g CaCl2, and 1.0 g citric acid (monohydrate) per liter of deionized water (resulting pH 5.1 +/- 0.1) and the assay organism Bacillus subtilis ATCC 6633. This system allows the assay of teicoplanin in the presence of commonly used aminoglycosides and in the presence of beta-lactams after inactivation by beta-lactamase. Additionally, it has the potential to be used in the presence of rifampin by using a rifampin-resistant strain of B. subtilis.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2529097     DOI： 10.1016/0732-8893(89)90020-5

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  12 in total

1.  Evaluation of a novel fluorescence polarization immunoassay for teicoplanin.

Authors:  H Cox; M Whitby; G Nimmo; G Williams
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

2.  Efficacy of vancomycin and teicoplanin alone and in combination with streptomycin in experimental, low-level vancomycin-resistant, VanB-type Enterococcus faecalis endocarditis.

Authors:  D P Nicolau; M N Marangos; C H Nightingale; K B Patel; B W Cooper; R Quintiliani; P Courvalin; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

3.  Comparison of vancomycin- and teicoplanin-induced histamine release and "red man syndrome".

Authors:  J Sahai; D P Healy; M J Shelton; J S Miller; S J Ruberg; R Polk
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

4.  Application of a modified bioassay for monitoring serum teicoplanin and vancomycin in febrile neutropenic patients.

Authors:  A Kureishi; P J Jewesson; K H Bartlett; C D Cole; A W Chow
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

5.  Teicoplanin pharmacokinetics in healthy volunteers after administration of intravenous loading and maintenance doses.

Authors:  W R Outman; C H Nightingale; K R Sweeney; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

6.  Pharmacokinetics of teicoplanin upon multiple-dose intravenous administration of 3, 12, and 30 milligrams per kilogram of body weight to healthy male volunteers.

Authors:  J A Smithers; H K Kulmala; G A Thompson; K K Antony; E W Lewis; S J Ruberg; M T Kenny; J K Dulworth; M A Brackman
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

7.  Population pharmacokinetics of teicoplanin in patients with endocarditis.

Authors:  D K Yu; E Nordbrock; S J Hutcheson; E W Lewis; W Sullivan; V O Bhargava; S J Weir
Journal:  J Pharmacokinet Biopharm       Date:  1995-02

8.  Intraocular penetration of rifampin in humans.

Authors:  W R Outman; R E Levitz; D A Hill; C H Nightingale
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

9.  Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditis.

Authors:  M J Rybak; S A Lerner; D P Levine; L M Albrecht; P L McNeil; G A Thompson; M T Kenny; L Yuh
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

10.  Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin.

Authors:  E M Bailey; M J Rybak; G W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.